Vermont Clinical Trials Report — July 2026

Vermont residents considering a clinical trial should check eligibility soon: 7 recruiting studies are expected to close within the next 90 days. Only 1 of those closing studies accepts healthy volunteers, so people interested in participating without a diagnosed condition have a particularly limited window. Statewide, 196 trials are recruiting across 10 cities and 50 research sites.

July brought just 1 newly opened trial, matching the number reported in May 2026 and continuing a recent decline from 5 new trials in February, 2 in March, and 3 in May. The new study is based in Bennington, focuses on emergency care, and is sponsored by Mayo Clinic. It is classified as an “other” type of study rather than a drug, device, or behavioral trial.

Closing dates create the most immediate opportunity

The seven studies approaching closure span urgent and complex medical needs. The conditions represented include acute leukemia, acute myeloid leukemia, AML with mutated NPM1, atrial fibrillation, bleeding, chemotherapy-induced peripheral neuropathy, heart failure, hematologic malignancy, and KMT2A-rearranged leukemia. Some condition labels overlap, such as acute myeloid leukemia and AML, so prospective participants should review each study’s detailed eligibility rather than relying on the condition category alone.

• Acute leukemia and related blood cancers, including acute myeloid leukemia, AML with mutated NPM1, hematologic malignancy, and KMT2A-rearranged disease
• Atrial fibrillation and heart failure
• Bleeding
• Chemotherapy-induced peripheral neuropathy

The data identify 1 closing-soon study that accepts healthy volunteers. That leaves healthy adults with little time to inquire, complete pre-screening, and arrange any required visits. The broader statewide pool is larger: 10 studies currently recruiting healthy volunteers. Because enrollment projections can change, anyone interested should verify that a study remains open before making travel or medical arrangements.

A single new study puts Bennington on July’s map

Vermont’s only new July trial opened in Bennington and addresses emergency care. Mayo Clinic is the named sponsor, giving the month’s new activity a recognizable academic-medical sponsor even though the study is not identified as a major Phase 2 or Phase 3 drug trial. No new study this month has a reported Phase 2 or Phase 3 designation or enrollment above 200 participants.

The new trial includes older adults, but the data show no new trials specifically including children, no female-only studies, and no male-only studies. Healthy volunteers are not eligible for the new Bennington study. People interested in emergency-care research should therefore focus on the study’s patient eligibility requirements and location rather than approaching it as a general volunteer opportunity.

• Mayo Clinic emergency-care study in Bennington — 1 new July trial
• New Phase 2 or Phase 3 trials — 0
• New trials with enrollment above 200 — 0
• New trials accepting healthy volunteers — 0

The absence of a large late-stage drug study makes July different from months when Vermont residents may see broader industry-sponsored treatment opportunities. This month’s opening is narrower, but it may be relevant to older adults who meet the medical requirements and can reach Bennington.

Research is available statewide, but July’s new activity is concentrated

Vermont’s recruiting network extends across 10 cities and 50 research sites, suggesting that opportunities are not limited to a single hospital or population center. However, all newly opened activity this month is concentrated in Bennington. That contrast matters for residents: the statewide database offers a wider range of ongoing studies, while the newest local opportunity is located in one city.

Patients should search by condition and travel distance rather than assuming the newest trial will be nearby. The most time-sensitive studies may be located in different communities from the July opening, particularly those involving leukemia, heart conditions, bleeding, or treatment-related nerve symptoms. Contacting a site directly can clarify whether a Vermont location is still screening participants and whether referrals are accepted.

Who should act now?

People with acute leukemia or related hematologic conditions should review the closing-soon listings first, especially those with acute myeloid leukemia, AML with mutated NPM1, or KMT2A-rearranged disease. Individuals with atrial fibrillation, heart failure, bleeding, or chemotherapy-induced peripheral neuropathy also face a time-sensitive search. Screening may require records, laboratory testing, or confirmation of prior treatment, so beginning the process before the projected closing date is essential.

Healthy adults have two reasons to look promptly. First, only 1 closing-soon study accepts healthy volunteers. Second, although 10 healthy-volunteer trials are recruiting statewide overall, the July opening does not add another option. Availability, age requirements, travel needs, and screening standards can differ substantially among these studies.

Older adults may have a clearer opening this month because 1 new trial includes them in its eligibility criteria. There are no new child-focused, female-only, or male-only trials reported for July. People outside those groups may still find ongoing studies among Vermont’s 196 recruiting trials, but the July data do not show new specialized opportunities for them.

What to watch through the rest of summer

Vermont’s recent pattern points to a smaller monthly flow of newly opened trials: activity fell from 5 new studies in February to 1 in July, after a brief rise to 3 in May. That makes the existing recruiting pool especially important for patients who do not match the single new emergency-care study.

Residents should monitor the seven studies nearing closure while also checking the broader network for replacements. New opportunities may emerge in additional Vermont cities, and studies sponsored by Mayo Clinic or other academic and medical institutions may continue to expand access for older adults and people with urgent cardiovascular, neurologic, and blood-related conditions. For anyone who finds a match, acting now can preserve the chance to complete screening before enrollment windows narrow.